BrainStorm Cell Therapeutics
Sub-category: Tissue Engineering & Cell Therapy
BrainStorm Cell Therapeutics is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm has developed a proprietary process for inducing autologous Mesenchymal Stem Cells (MSC) to differentiate into neurotrophic factor (NTF) secreting cells (MSC-NTF cells; NurOwn®) while maintaining the important immunomodulatory capacities of the MSC cell.
BrainStorm is currently enrolling a Phase 3 pivotal trial in Amyotrophic Lateral Sclerosis (ALS NCT03280056), investigating repeat-administration of autologous MSC-NTF cells and has initiated a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis.
|Chaim Lebovits, CEO|
|Rehov Basel 12, Peatch Tikva|
To update your company data, click here.